FDA DEVICE FACTS
Quest Diagnostics AAVrh74 Antibody ELISA CDx
Quest Diagnostics Nichols Institute
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Quest Diagnostics AAVrh74 Antibody ELISA CDx is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi -quantitative detection of antibodies (IgG) to AAVrh74 capsid in human serum. The test reports an antibody titer, and a semi-quantitative interpretation of the test results derived from the antibody titer. Patients with an AAVrh74 antibody titer <1:400 are reported as not elevated for AAVrh74 antibody titers and may be eligible for treatment with the gene therapy . Patients with an AAVrh74 antibody titer ≥1:400 are reported as elevated for AAVrh74 antibody titers and are ineligible for treatment with the gene therapy . The test is for prescription use only. The test is intended to be used in conjunction with other available clinical information as an aid to identify patients eligible for treatment with indicated gene therapies.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。